Results 61 to 70 of about 327 (169)

Эффективность персонализированной антитромботической терапии при стентировании коронарных артерий: метаанализ

open access: yes
Background. Prevention of complications in patients after coronary stenting by selection of personalized antiplatelet therapy (PAPT) based on platelet function test and genetic analysis have been actively studied. However, it is still an issue of concern.
Danishian K.I.   +7 more
core  

[Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice]. [PDF]

open access: yesProbl Endokrinol (Mosk), 2022
Kuznetsov KO   +10 more
europepmc   +1 more source

[Hypothyroidism and aging: the search for protective factors]. [PDF]

open access: yesProbl Endokrinol (Mosk), 2023
Ilyushchenko AK   +2 more
europepmc   +1 more source

Метаанализ исследований, посвященных прогностической значимости циркулирующей опухолевой ДНК при раке поджелудочной железы

open access: yes
The method of liquid biopsy allows detection of circulating tumor DNA (ctDNA) in patient blood, but the clinical significance of this approach in pancreatic cancer is still unclear.
Покатаев И.А.   +3 more
core  

[Contraception in adolescents with obesity and diabetes mellitus]. [PDF]

open access: yesProbl Endokrinol (Mosk), 2022
Shaydullina MR   +3 more
europepmc   +1 more source

[The dual role of the menopausal hormonal therapy as the enhancer of pleiotropic telomere rejuvenation and the silencer of cellular aging (literature review)]. [PDF]

open access: yesProbl Endokrinol (Mosk), 2022
Grigoryan OR   +7 more
europepmc   +1 more source

Rapid diagnostic tests versus RT-PCR for Ebola virus infections: a systematic review and meta-analysis. [PDF]

open access: yesBull World Health Organ, 2022
Muzembo BA   +6 more
europepmc   +1 more source

Метаанализ исследований по сравнению эффективности режимов FOLFOXIRI и FOLFOX или FOLFIRI с таргетной терапией при метастатическом раке толстой кишки с мутацией в гене BRAF

open access: yes
Introduction. Based on the subgroup analysis of the TRIBE study FOLFOXIRI with bevacizumab is the recommended option for patients (pts) with mBRAF metastatic colorectal cancer (mCRC) in the 1st line.
Трякин А.А.   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy